Elevance Health, Inc. (ELV) Q3 FY2026 Financial Statements: Revenue $51.43B, Net income $1.36B
More for Elevance Health: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ3 FY2026
Published
Elevance Health reported $51.43 billion in revenue for Q3 FY2026, the quarter ended September 30, 2026, up 1.4% from a year earlier, and net income attributable to shareholders of $1.36 billion, up 14.8%, or $6.27 per diluted share, up 17.9%. Higher net investment income, $1.04 billion against $625 million a year earlier, drove the increase, while total operating gain across its segments was $1.27 billion, down 2.0%. The benefit expense ratio, benefit expense as a percentage of premiums, was 90.6%, down 0.7 points from a year earlier.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $51,429,000,000 | up 1.4% |
| Net income | $1,365,000,000 | up 14.8% |
| Diluted EPS | $6.27 | up 17.9% |
| Benefit expense ratio | 90.6% | down 0.7 points |
| Net investment income | $1,037,000,000 | up 65.9% |
| Operating gain | $1,269,000,000 | down 2.0% |
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. Figures calculated here, such as margins, free cash flow and trailing-twelve-month totals, have no line in a filing to point to and are not linked.
About this file
| Ticker | ELV |
|---|---|
| CIK | 0001156039 |
| Company | Elevance Health, Inc. |
| Business type | insurer |
| Schema template | Managed care / health benefits insurer: revenue split the way the company reports it (premiums, product revenue, service fees, then net investment income and net losses on financial instruments); expenses on the company's own lines (benefit expense, cost of products sold, operating expense, interest expense, amortization of other intangible assets); income before tax, net income, shareholders' net income and per-share figures; the benefit expense ratio (benefit expense as a percentage of premiums) and operating expense ratio the company reports; total medical membership; operating revenue and operating gain by reportable segment (Health Benefits, CarelonRx, Carelon Services, Corporate & Other); and a balance sheet and cash flow on the company's own lines. Gross profit is not used because the company does not present one. |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual dollars (not millions); share counts in actual shares (not millions); medical membership in actual members (not thousands); per-share amounts in dollars; ratios in percent. Figures keep the sign the statement prints: amounts shown in parentheses (net losses on financial instruments, cash outflows) are negative; expenses the income statement prints without parentheses are positive. |
ELV annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 10-K | 10-K | 10-K |
| Income statement | |||
| Premiums | 164,639,000,000 | 144,166,000,000 | 142,854,000,000 |
| Product revenue | 24,470,000,000 | 22,630,000,000 | 19,452,000,000 |
| Service fees | 8,475,000,000 | 8,408,000,000 | 7,903,000,000 |
| Total operating revenue | 197,584,000,000 | 175,204,000,000 | 170,209,000,000 |
| Net investment income | 2,194,000,000 | 2,051,000,000 | 1,825,000,000 |
| Net losses on financial instruments | -653,000,000 | -445,000,000 | -694,000,000 |
| Gain on sale of business | 0 | 201,000,000 | 0 |
| Total revenues | 199,125,000,000 | 177,011,000,000 | 171,340,000,000 |
| Benefit expense | 148,223,000,000 | 127,567,000,000 | 124,330,000,000 |
| Cost of products sold | 21,178,000,000 | 19,750,000,000 | 17,293,000,000 |
| Operating expense | 20,984,000,000 | 20,025,000,000 | 20,087,000,000 |
| Interest expense | 1,402,000,000 | 1,185,000,000 | 1,030,000,000 |
| Amortization of other intangible assets | 628,000,000 | 580,000,000 | 885,000,000 |
| Total expenses | 192,415,000,000 | 169,107,000,000 | 163,625,000,000 |
| Income before income tax expense | 6,710,000,000 | 7,904,000,000 | 7,715,000,000 |
| Income tax expense | 1,049,000,000 | 1,933,000,000 | 1,724,000,000 |
| Net income | 5,661,000,000 | 5,971,000,000 | 5,991,000,000 |
| Net loss attributable to noncontrolling interests | 1,000,000 | 9,000,000 | -4,000,000 |
| Net income attributable to shareholders | 5,662,000,000 | 5,980,000,000 | 5,987,000,000 |
| Basic EPS | 25.28 | 25.81 | 25.38 |
| Diluted EPS | 25.21 | 25.68 | 25.22 |
| Basic shares | 224,000,000 | 231,700,000 | 235,900,000 |
| Diluted shares | 224,600,000 | 232,900,000 | 237,400,000 |
| Key metrics | |||
| Effective tax rate percent | 15.6 | 24.5 | 22.3 |
| Benefit expense ratio percent | 90.0 | 88.5 | 87.0 |
| Operating expense ratio percent | 10.6 | 11.4 | 11.8 |
| Total medical membership | 45,232,000 | 45,734,000 | 46,829,000 |
| Book value per share derived | 198.81 | 181.62 | |
| Segments | |||
| Operating revenue | |||
| Health benefits | 167,094,000,000 | 150,275,000,000 | 148,571,000,000 |
| Carelonrx | 43,400,000,000 | 35,961,000,000 | 33,835,000,000 |
| Carelon services | 28,316,000,000 | 17,961,000,000 | 14,147,000,000 |
| Corporate and other | 463,000,000 | 309,000,000 | 479,000,000 |
| Eliminations | -41,689,000,000 | -29,302,000,000 | -26,823,000,000 |
| Total | 197,584,000,000 | 175,204,000,000 | 170,209,000,000 |
| Operating gain | |||
| Health benefits | 4,158,000,000 | 6,243,000,000 | 6,888,000,000 |
| Carelonrx | 2,418,000,000 | 2,172,000,000 | 1,975,000,000 |
| Carelon services | 960,000,000 | 717,000,000 | 680,000,000 |
| Corporate and other | -337,000,000 | -1,270,000,000 | -1,044,000,000 |
| Eliminations | 0 | 0 | 0 |
| Total | 7,199,000,000 | 7,862,000,000 | 8,499,000,000 |
| Balance sheet | |||
| Cash and cash equivalents | 9,491,000,000 | 8,288,000,000 | |
| Fixed maturity securities current | 25,884,000,000 | 25,201,000,000 | |
| Equity securities | 740,000,000 | 1,192,000,000 | |
| Premium receivables | 10,073,000,000 | 8,011,000,000 | |
| Self funded receivables | 5,162,000,000 | 5,044,000,000 | |
| Other receivables | 6,307,000,000 | 6,016,000,000 | |
| Total current assets | 63,001,000,000 | 58,942,000,000 | |
| Fixed maturity securities long term | 1,121,000,000 | 1,035,000,000 | |
| Other invested assets | 10,839,000,000 | 9,749,000,000 | |
| Goodwill | 28,344,000,000 | 28,277,000,000 | |
| Other intangible assets | 11,200,000,000 | 12,094,000,000 | |
| Total assets | 121,494,000,000 | 116,889,000,000 | |
| Medical claims payable | 17,084,000,000 | 15,746,000,000 | |
| Short term borrowings | 150,000,000 | 365,000,000 | |
| Current portion of long term debt | 1,099,000,000 | 1,649,000,000 | |
| Total current liabilities | 41,035,000,000 | 40,581,000,000 | |
| Long term debt less current portion | 30,797,000,000 | 29,218,000,000 | |
| Total liabilities | 77,468,000,000 | 75,463,000,000 | |
| Total shareholders equity | 43,882,000,000 | 41,315,000,000 | |
| Noncontrolling interests | 144,000,000 | 111,000,000 | |
| Total equity | 44,026,000,000 | 41,426,000,000 | |
| Total debt | 32,046,000,000 | 31,232,000,000 | |
| Common shares outstanding | 220,723,898 | 227,479,695 | |
| Cash flow | |||
| Net income | 5,661,000,000 | 5,971,000,000 | 5,991,000,000 |
| Depreciation and amortization | 1,546,000,000 | 1,393,000,000 | 1,745,000,000 |
| Net cash provided by operating activities | 4,290,000,000 | 5,808,000,000 | 8,061,000,000 |
| Purchases of property and equipment | -1,116,000,000 | -1,256,000,000 | -1,296,000,000 |
| Net cash used in investing activities | -1,344,000,000 | -5,167,000,000 | -5,572,000,000 |
| Repurchase and retirement of common stock | -2,605,000,000 | -2,900,000,000 | -2,676,000,000 |
| Cash dividends | -1,529,000,000 | -1,508,000,000 | -1,395,000,000 |
| Net cash provided by used in financing activities | -1,738,000,000 | 1,193,000,000 | -3,349,000,000 |
| Cash and cash equivalents at end of period | 9,491,000,000 | 8,288,000,000 | 6,526,000,000 |
| Free cash flow | 3,174,000,000 | 4,552,000,000 | 6,765,000,000 |
ELV quarterly income statement, balance sheet and cash flow
| Q3 FY2026 | Q3 FY2025 | |
|---|---|---|
| Fiscal quarter | 3 | 3 |
| Period start | 2026-07-01 | 2025-07-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | three months | three months |
| Source accession | 10-Q | 10-Q |
| Income statement | ||
| Premiums | 41,704,000,000 | 41,791,000,000 |
| Product revenue | 6,454,000,000 | 6,159,000,000 |
| Service fees | 2,282,000,000 | 2,137,000,000 |
| Total operating revenue | 50,440,000,000 | 50,087,000,000 |
| Net investment income | 1,037,000,000 | 625,000,000 |
| Net losses on financial instruments | -48,000,000 | -1,000,000 |
| Total revenues | 51,429,000,000 | 50,711,000,000 |
| Benefit expense | 37,779,000,000 | 38,140,000,000 |
| Cost of products sold | 5,640,000,000 | 5,380,000,000 |
| Operating expense | 5,752,000,000 | 5,272,000,000 |
| Interest expense | 358,000,000 | 351,000,000 |
| Amortization of other intangible assets | 106,000,000 | 162,000,000 |
| Total expenses | 49,635,000,000 | 49,305,000,000 |
| Income before income tax expense | 1,794,000,000 | 1,406,000,000 |
| Income tax expense | 451,000,000 | 219,000,000 |
| Net income | 1,343,000,000 | 1,187,000,000 |
| Net loss attributable to noncontrolling interests | 22,000,000 | 2,000,000 |
| Net income attributable to shareholders | 1,365,000,000 | 1,189,000,000 |
| Basic EPS | 6.30 | 5.32 |
| Diluted EPS | 6.27 | 5.32 |
| Basic shares | 216,600,000 | 223,300,000 |
| Diluted shares | 217,600,000 | 223,700,000 |
| Key metrics | ||
| Dividends per share | 1.72 | 1.71 |
| Effective tax rate percent | 25.1 | 15.6 |
| Benefit expense ratio percent | 90.6 | 91.3 |
| Operating expense ratio percent | 11.4 | 10.5 |
| Total medical membership | 44,882,000 | 45,369,000 |
| Book value per share derived | 206.75 | |
| Segments | ||
| Operating revenue | ||
| Health benefits | 43,357,000,000 | 42,246,000,000 |
| Carelonrx | 11,599,000,000 | 10,997,000,000 |
| Carelon services | 7,708,000,000 | 7,324,000,000 |
| Corporate and other | 6,000,000 | 149,000,000 |
| Eliminations | -12,230,000,000 | -10,629,000,000 |
| Total | 50,440,000,000 | 50,087,000,000 |
| Operating gain | ||
| Health benefits | 436,000,000 | 601,000,000 |
| Carelonrx | 616,000,000 | 556,000,000 |
| Carelon services | 292,000,000 | 219,000,000 |
| Corporate and other | -75,000,000 | -81,000,000 |
| Eliminations | 0 | 0 |
| Total | 1,269,000,000 | 1,295,000,000 |
| Balance sheet | ||
| Cash and cash equivalents | 10,348,000,000 | |
| Fixed maturity securities current | 25,347,000,000 | |
| Equity securities | 2,151,000,000 | |
| Premium receivables | 10,686,000,000 | |
| Self funded receivables | 6,277,000,000 | |
| Other receivables | 7,610,000,000 | |
| Total current assets | 68,524,000,000 | |
| Fixed maturity securities long term | 1,211,000,000 | |
| Other invested assets | 11,508,000,000 | |
| Goodwill | 28,343,000,000 | |
| Other intangible assets | 10,877,000,000 | |
| Total assets | 127,801,000,000 | |
| Medical claims payable | 18,438,000,000 | |
| Short term borrowings | 0 | |
| Current portion of long term debt | 375,000,000 | |
| Total current liabilities | 46,662,000,000 | |
| Long term debt less current portion | 30,382,000,000 | |
| Total liabilities | 83,007,000,000 | |
| Total shareholders equity | 44,681,000,000 | |
| Noncontrolling interests | 113,000,000 | |
| Total equity | 44,794,000,000 | |
| Total debt | 30,757,000,000 | |
| Common shares outstanding | 216,113,946 | |
ELV year-to-date income statement and cash flow
| Nine months ended September 30, 2026 | Nine months ended September 30, 2025 | |
|---|---|---|
| Period start | 2026-01-01 | 2025-01-01 |
| Period end | 2026-09-30 | 2025-09-30 |
| Period type | nine months | nine months |
| Source accession | 10-Q | 10-Q |
| Income statement | ||
| Premiums | 124,007,000,000 | 123,949,000,000 |
| Product revenue | 18,943,000,000 | 18,010,000,000 |
| Service fees | 6,810,000,000 | 6,314,000,000 |
| Total operating revenue | 149,760,000,000 | 148,273,000,000 |
| Net investment income | 2,506,000,000 | 1,701,000,000 |
| Net losses on financial instruments | -182,000,000 | -596,000,000 |
| Total revenues | 152,084,000,000 | 149,378,000,000 |
| Benefit expense | 110,418,000,000 | 110,158,000,000 |
| Cost of products sold | 16,595,000,000 | 15,656,000,000 |
| Operating expense | 17,629,000,000 | 15,569,000,000 |
| Interest expense | 1,079,000,000 | 1,036,000,000 |
| Amortization of other intangible assets | 328,000,000 | 464,000,000 |
| Total expenses | 146,049,000,000 | 142,883,000,000 |
| Income before income tax expense | 6,035,000,000 | 6,495,000,000 |
| Income tax expense | 1,478,000,000 | 1,380,000,000 |
| Net income | 4,557,000,000 | 5,115,000,000 |
| Net loss attributable to noncontrolling interests | 35,000,000 | 0 |
| Net income attributable to shareholders | 4,592,000,000 | 5,115,000,000 |
| Basic EPS | 21.08 | 22.73 |
| Diluted EPS | 21.01 | 22.67 |
| Basic shares | 217,800,000 | 225,000,000 |
| Diluted shares | 218,600,000 | 225,600,000 |
| Key metrics | ||
| Dividends per share | 5.16 | 5.13 |
| Effective tax rate percent | 24.5 | 21.2 |
| Benefit expense ratio percent | 89.0 | 88.9 |
| Operating expense ratio percent | 11.8 | 10.5 |
| Segments | ||
| Operating revenue | ||
| Health benefits | 128,567,000,000 | 125,259,000,000 |
| Carelonrx | 33,449,000,000 | 31,756,000,000 |
| Carelon services | 23,048,000,000 | 21,301,000,000 |
| Corporate and other | 16,000,000 | 546,000,000 |
| Eliminations | -35,320,000,000 | -30,589,000,000 |
| Total | 149,760,000,000 | 148,273,000,000 |
| Operating gain | ||
| Health benefits | 3,489,000,000 | 4,378,000,000 |
| Carelonrx | 1,780,000,000 | 1,694,000,000 |
| Carelon services | 1,128,000,000 | 1,110,000,000 |
| Corporate and other | -1,279,000,000 | -292,000,000 |
| Eliminations | 0 | 0 |
| Total | 5,118,000,000 | 6,890,000,000 |
| Cash flow | ||
| Net income | 4,557,000,000 | 5,115,000,000 |
| Depreciation and amortization | 1,083,000,000 | 1,140,000,000 |
| Net cash provided by operating activities | 7,512,000,000 | 4,206,000,000 |
| Purchases of property and equipment | -789,000,000 | -823,000,000 |
| Net cash used in investing activities | -3,470,000,000 | -1,808,000,000 |
| Repurchase and retirement of common stock | -1,688,000,000 | -2,134,000,000 |
| Cash dividends | -1,122,000,000 | -1,152,000,000 |
| Net cash provided by used in financing activities | -3,171,000,000 | -1,974,000,000 |
| Cash and cash equivalents at end of period | 10,348,000,000 | 8,713,000,000 |
| Free cash flow | 6,723,000,000 | 3,383,000,000 |
ELV trailing twelve month income statement and cash flow
| Twelve months ended September 30, 2026 | |
|---|---|
| Period start | 2025-10-01 |
| Period end | 2026-09-30 |
| Period type | trailing twelve months |
| Source accession | 10-Q |
| Source accessions | 10-K, 10-Q |
| Income statement | |
| Premiums | 164,697,000,000 |
| Total operating revenue | 199,071,000,000 |
| Total revenues | 201,831,000,000 |
| Benefit expense | 148,483,000,000 |
| Operating expense | 23,044,000,000 |
| Income before income tax expense | 6,250,000,000 |
| Net income | 5,103,000,000 |
| Net income attributable to shareholders | 5,139,000,000 |
| Cash flow | |
| Net cash provided by operating activities | 7,596,000,000 |
| Purchases of property and equipment | -1,082,000,000 |
| Free cash flow | 6,514,000,000 |
- Derivation. Computed, not printed in either filing: full year 2025 from the FY2025 10-K (accession 0001156039-26-000013), plus the nine months ended September 30, 2026, less the nine months ended September 30, 2025, both from the Q3 2026 10-Q (accession 0001156039-26-000071).
Adjustments
| Splits applied | none |
|---|---|
| ADR ratio | n/a |
| FX | n/a |
| Note | None applied. The company reports in US dollars, its common stock trades directly on the NYSE (it is not an American depositary share), and it had no stock split in the periods shown. |
Notes
- Sources: the FY2025 annual report on Form 10-K (accession 0001156039-26-000013) for fiscal years 2025, 2024 and 2023, and the Q3 2026 quarterly report on Form 10-Q (accession 0001156039-26-000071) for the three and nine months ended September 30, 2026 and 2025 and the September 30, 2026 balance sheet. Elevance Health's fiscal year is the calendar year.
- Template: managed care / health benefits insurer. Revenue is shown as the company reports it: premiums, product revenue (mainly CarelonRx pharmacy) and service fees make up total operating revenue; net investment income and net losses on financial instruments bring it to total revenues. The company does not present gross profit or an operating income subtotal, so neither is shown.
- Signs follow the statements: expenses the income statement prints without parentheses are positive; net losses on financial instruments and cash outflows (purchases of property and equipment, share repurchases, dividends) are negative.
- net_loss_attributable_to_noncontrolling_interests is shown as the income statement prints it: a positive figure is a loss borne by noncontrolling interests, which is added back to net income to reach shareholders' net income; FY2023's negative figure is a gain attributable to noncontrolling interests. Shareholders' net income (net_income_attributable_to_shareholders) is the numerator of the company's earnings per share.
- Weighted-average basic and diluted shares come from the earnings-per-share note of each filing, where they are stated in millions.
- Benefit expense ratio (benefit expense as a percentage of premiums), operating expense ratio (operating expense as a percentage of total operating revenue) and effective tax rate are the percentages the company prints in management's discussion and analysis, not recomputed.
- Total medical membership is the company's count of medical members at the end of each period, reported in thousands and shown here as actual members.
- Segment figures come from the segment information note. Operating revenue by segment includes revenue earned from other Elevance Health businesses; the eliminations line removes it, so the segments plus eliminations equal consolidated total operating revenue. Operating gain is the company's segment profit measure: total operating revenue less benefit expense, cost of products sold and operating expense. It is before net investment income, net losses on financial instruments, interest expense, amortization of other intangible assets and income taxes.
- Dividends per share are as printed on the 10-Q income statement for the quarterly and nine-month periods; the 10-K income statement does not print an annual figure, so none is shown for the fiscal years.
- Derived figures, not printed as such in the filings: free_cash_flow is net cash provided by operating activities less purchases of property and equipment; total_debt is short-term borrowings plus the current portion of long-term debt plus long-term debt less current portion; book_value_per_share_derived is total shareholders' equity (excluding noncontrolling interests) divided by the common shares outstanding stated on the balance sheet.
- common_shares_outstanding is the issued and outstanding count stated on the face of each balance sheet (220,723,898 at December 31, 2025; 227,479,695 at December 31, 2024; 216,113,946 at September 30, 2026).
- The trailing twelve months ended September 30, 2026 are computed as fiscal year 2025 (10-K, accession 0001156039-26-000013) plus the nine months ended September 30, 2026 less the nine months ended September 30, 2025 (10-Q, accession 0001156039-26-000071). Per-share figures are not computed for this period.
- The 10-Q's December 31, 2025 balance sheet column folds reserves for future policy benefits ($145 million in the 10-K) into other noncurrent liabilities ($3,526 million versus $3,381 million in the 10-K). None of the balance sheet lines carried here is affected; every December 31, 2025 figure shown agrees between the two filings.
Uncertainties
- No three-month cash flow figures are shown for the quarters: the Q3 2026 10-Q prints only nine-month cash flows, and the second-quarter figures needed to isolate the third quarter are not in the filings this page is built from.
- No balance sheet is shown for September 30, 2025 or December 31, 2023, because neither filing prints one.
- Gain on sale of business appears only on the 10-K income statement (FY2024: $201 million); the 10-Q does not print the line, so it is absent from the quarterly and nine-month periods rather than shown as zero.
Company details
| Name | Elevance Health, Inc. |
|---|---|
| Ticker | ELV |
| CIK | 0001156039 |
| Exchange | NYSE |
| State | Indiana |
| Incorporation | Indiana |
| SIC | 6324 |
| Office | Finance |
| Industry | Hospital & Medical Service Plans |
Fiscal period
| Fiscal year | 2026 |
|---|---|
| Fiscal period | Q3 |
| Tag | FY26Q3 |
| Period end | 2026-09-30 |
| Form | 10-Q |
| Accession | 0001156039-26-000071 |
| Fiscal year end | 1231 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Source |
|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-12-31 | 2026-02-06 | 0001156039-26-000013 | reported |
| quarterly | yes | 10-Q | 2026 | Q3 | FY26Q3 | 2026-09-30 | 2026-10-21 | 0001156039-26-000071 | facts |
FAQ · Elevance Health financial statements
What was Elevance Health's revenue in Q3 FY2026?
Elevance Health reported total revenues of $51.43 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 1.4% from $50.71 billion in the same quarter a year earlier.
How much did Elevance Health earn in Q3 FY2026?
Elevance Health's net income attributable to shareholders was $1.36 billion in Q3 FY2026, up 14.8% from $1.19 billion a year earlier. Diluted earnings per share were $6.27, against $5.32 in the same quarter a year earlier.
What was Elevance Health's benefit expense ratio in Q3 FY2026?
Elevance Health's benefit expense ratio, benefit expense as a percentage of premiums, was 90.6% in Q3 FY2026, down 0.7 points from 91.3% a year earlier.
Why did Elevance Health's earnings rise in Q3 FY2026?
Elevance Health's earnings rose in Q3 FY2026 mainly on higher net investment income, which was $1.04 billion against $625 million a year earlier. Total operating gain across its segments, measured before investment results, interest expense, amortization of intangible assets and income taxes, was $1.27 billion, down 2.0% from $1.29 billion.
Where can I get Elevance Health, Inc. (ELV) financial data in machine-readable form?
Ticker Scout publishes Elevance Health, Inc.'s financial statements as JSON at https://tickerscout.ai/elv/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/elv/narrative.md and https://tickerscout.ai/elv/events.md. Elevance Health, Inc.'s SEC CIK is 0001156039. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Elevance Health, Inc. (ELV) next file with the SEC?
Elevance Health, Inc. (ELV) is expected to file its next Form 10-K with the SEC on or around February 5, 2027. That date is a projection rather than a company-announced date: it is derived from Elevance Health, Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q3 FY2026, the period ended 2026-09-30, SEC accession 0001156039-26-000071.
Related companies
How this page was built
This page was built from two of Elevance Health, Inc.'s own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names three such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Elevance Health, Inc.'s SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.